PAVmed Welcomes Joseph Virgilio to Steer Innovative Medical Device Initiative

Major Changes at PAVmed: New Leadership to Propel Medical Device Innovations

PAVmed Inc. has recently made headlines with the announcement of Joseph Virgilio as the new Senior Vice President and Chief Business Officer for its medical devices segment. His role will be pivotal in spearheading the relaunch of PAVmed's medical device portfolio, which aims to leverage innovative technologies and address critical healthcare needs.

A Strategic Appointment

PAVmed, a diverse medical technology company listed on Nasdaq (PAVM), is no stranger to the healthcare innovation sector. With the appointment of Virgilio—a seasoned veteran with over 25 years in the medical device industry—the company is positioning itself to advance its product strategies significantly. Under his direction, PAVmed intends to oversee both the current and forthcoming medical devices, ensuring robust development and commercialization processes.

Lishan Aklog, M.D., PAVmed's Chairman and CEO, expressed optimism about Virgilio's extensive experience. Aklog stated, "Fixing PAVmed's capital structure and strengthening our balance sheet has allowed us to relaunch our medical device portfolio under dedicated, experienced leadership." This strategic move is seen as a step toward enhancing shareholder value while driving growth in the long term.

Virgilio's Track Record

Before joining PAVmed, Joseph Virgilio held leadership positions at Morphic Medical and various other renowned companies. Notably, during his tenure at Morphic Medical, he was instrumental in advancing product strategies and securing over $40 million in capital to support growth initiatives. His expertise encompasses the entire product lifecycle—from developmental stages to regulatory approvals and commercialization efforts, making him a resourceful asset for PAVmed.

Virgilio's past roles at companies such as Boston Scientific and Medtronic have equipped him with the knowledge to drive innovative medical technology adoption effectively. He has also engaged in industry-wide leadership roles, collaborating with organizations like AdvaMed, which enhances his capability to navigate the complex landscape of medical device commercialization.

Focus on Innovation

Virgilio expressed enthusiasm about the future of PAVmed, stating, "PAVmed has already established a strong foundation with its existing medical device programs, and I'm excited to build on that momentum." This philosophy underscores his commitment to developing high-quality products while exploring new avenues to diversify the company's offerings.

Under his stewardship, the medical device portfolio will not only include existing products but will also expand into new technologies that complement PAVmed’s objectives. For instance, the PortIO implantable intraosseous vascular access device will play a crucial role in providing rapid medical treatment through direct access to the bone marrow. This innovative approach aims to transform how medical professionals deliver critical therapies.

Additionally, PAVmed has formed Octeris, Inc., a subsidiary established to enhance endoscopic esophageal imaging technology licensed from Duke University. This partnership is expected to improve the management of esophageal conditions, an area of growing concern in healthcare.

Future Prospects

The commitment to improving its medical device portfolio reflects PAVmed's broader mission to emerge as a high-growth life sciences company. The guidance of Virgilio will be paramount in navigating the company's strategic vision, focusing on disciplined execution while securing dedicated capital to ensure successful advancements.

PAVmed is actively pursuing new medical device opportunities, specifically those that align with the existing product spectrum. Technologies focusing on gastroesophageal reflux are of particular interest, which could catalyze further growth within the company’s portfolio.

As the healthcare landscape continues to evolve, PAVmed's proactive approach under Joseph Virgilio's leadership is set to align the company with market demands effectively. By concentrating on innovative solutions, PAVmed aims to enhance its competitive position within the medical technology sphere, ultimately benefiting patients and shareholders alike. The forthcoming developments promise to propel PAVmed into a new era of success, centered around meeting critical healthcare needs with cutting-edge solutions.

For further details about PAVmed and its subsidiaries, visit pavmed.com.